Neurontin generics “approvable”
Executive Summary
Ivax, Eon and Purepac ANDAs for generic versions of Pfizer's Neurontin (gabapentin) are "approvable" at FDA pending resolution of language in labeling referring prescribers to Pfizer's label for protected pediatric information. After labeling issues are resolved, the ANDAs will be tentatively approved until the 30-month stay of approval related to Pfizer's "lactam-free" bulk gabapentin expires in December (1"The Pink Sheet" Dec. 24, 2001, p. 18)...
You may also be interested in...
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.